Study of the PARP inhibitor AZD9574 Alone and Combined with Other Cancer Medicines to Treat People with Advanced Solid Cancers (CERTIS1 Study) identifier:
NCT05417594 (

Treatment study for people with advanced breast, ovarian, pancreatic or prostate cancer or gliomas

Study Contact Information:

For additional information, please contact:

AstraZeneca Clinical Study Information Center by phone: 1-877-240-9479 or email: [email protected]

About the Study

This research involves studying a drug called AZD9574 on its own and in combination with other anti-cancer drugs in people with advanced cancer that has come back or progressed. AZD9574 is a type of targeted therapy known as a PARP inhibitor. The study aims to understand the safety, tolerance, how the drug moves in the body, how it affects the body, and its initial effectiveness.

What the Study Involves

People will be enrolled and assigned to study treatments. This study consists of individual groups each evaluating the safety and effectiveness of the drug AZD9574.

Study Groups:

Group 1

Group 2

Study Sites - United States




New York



Study Sites - International


This Study is Open To:

People who:

Group 1 participants who:

Group 2 participants must also meet these criteria:

This Study is Not Open To:

People who:


FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.